Compare Crispr Therapeutics AG (CRSP) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Invesco Preferred ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Invesco Preferred ETF trades at $10.01 (market cap $3.60B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Invesco Preferred ETF for 95 Days on average.
| CRSP | PGX | |
|---|---|---|
Market Cap | $4.88B | $3.60B |
Volume | 2,861,747 | 5,986,026 |
Sector | Health | — |
52-Week High | $74.92 | $11.61 |
52-Week Low | $44.34 | $9.97 |
Typical Hold Time | 77 Days | 95 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
PGX trades at $10.01 with a modest 0.4% daily gain, but technical indicators signal a bearish trend with moving averages unanimously negative. The stock shows neutral oscillators with RSI levels suggesting potential oversold conditions. Recent corporate actions include scheduled dividends for July and September 2026 at $0.06 per share. Support and resistance levels cluster tightly around $10, indicating consolidation near current price levels.
Investment outlook remains cautious given the bearish technical picture and lack of current fundamental data. The stock faces headwinds from technical selling pressure while dividend payments provide some income support. Key risks include market volatility and the need for improved fundamental performance to sustain price levels above current support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
